The Roskamp Institute is Participating in a New Phase III MS Study ...
PR Newswire (press release) - New York,NY,USA
"If the Phase III study program confirms the data demonstrated in the Phase II study program and leads to FDA approval, FTY720 may represent an improvement ...
See all stories on this topic

Healthy Living: Miracle Drug For MS Sufferers
KUTV - Salt Lake City,UT,USA
Tysabri works by blocking these damaging cells. Doctor John Foley specializes in MS and says results of this drug are very promising. ...
See all stories on this topic

Research and Development on Crohn's Disease & Ulcerative Colitis
Business Wire (press release) - San Francisco,CA,USA
... while despite the fact that Tysabri’s (natalizumab/VLA-4) safety will dampen initial uptake, the product’s novel mechanism and efficacy could enable it ...
See all stories on this topic